Cigna, Express Scripts To Face Tough Antitrust Review

Law360 (March 15, 2018, 8:17 PM EDT) -- Cigna's $67 billion purchase of Express Scripts is set to face rigorous antitrust scrutiny amid a wave of deals integrating insurers and pharmacy benefits managers — especially given the government's recent hard-line stance on another high-profile vertical merger.

Historically, the U.S. Department of Justice and Federal Trade Commission haven’t have gone after mergers between companies that aren’t direct competitors, but the DOJ's decision to take AT&T Inc. to court over its $85.4 billion vertical deal for Time Warner Inc. has the antitrust bar wondering whether the tides...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.